Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the... see more

TSX:RVX - Post Discussion

Resverlogix Corp > The 50 day
View:
Post by Jkj193741 on Nov 20, 2022 11:41am

The 50 day

Resverlogix (TSE:RVX) Stock Crosses Above 50-Day Moving Average of $0.19
Posted by MarketBeat News on Nov 19th, 2022
Share on Twitter Share on Facebook Share on LinkedIn Share on Stocktwits
 
Resverlogix Corp. (TSE:RVX – Get Rating) passed above its 50 day moving average during trading on Friday . The stock has a 50 day moving average of C$0.19 and traded as high as C$0.19. Resverlogix shares last traded at C$0.19, with a volume of 18,069 shares changing hands.
Resverlogix Stock Performance
The firm has a market cap of C$48.66 million and a P/E ratio of -1.27. The company has a 50 day moving average of C$0.19 and a 200 day moving average of C$0.24.
About Resverlogix
(Get Rating)
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs. It is developing apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trial for patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease, and neurodegenerative diseases.
 
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities